Corcept Therapeutics (NASDAQ:CORT) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

Key Points

• Canaccord Genuity raised its price target to $110 and maintained a "buy" rating—implying roughly a 184% upside—while MarketBeat shows a consensus of "Moderate Buy" with a $77.67 target and mixed analyst ratings.
• FDA approval of Lifyorli (relacorilant) for platinum‑resistant ovarian cancer is the primary commercial catalyst for the recent sharp rally, but the news has produced elevated intraday volatility and temporary trading halts.
• Corcept missed quarterly estimates (EPS $0.20 vs. $0.33; revenue $202.1M vs. $254.9M) and faces legal risk from multiple securities‑class‑action filings; insider activity was mixed, including a director purchase of ~100,000 shares and other insider sales.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) had its price objective boosted by Canaccord Genuity Group from $100.00 to $110.00 in a report issued on Thursday,Benzinga reports. The firm presently has a "buy" rating on the biotechnology company's stock. Canaccord Genuity Group's price objective would indicate a potential upside of 184.46% from the stock's current price.

Other analysts also recently issued research reports about the stock. Wolfe Research raised shares of Corcept Therapeutics from an "underperform" rating to a "peer perform" rating in a research report on Thursday. HC Wainwright dropped their target price on shares of Corcept Therapeutics from $67.00 to $60.00 and set a "buy" rating on the stock in a research report on Wednesday. UBS Group began coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They set a "neutral" rating and a $95.00 target price on the stock. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Finally, Truist Financial upgraded shares of Corcept Therapeutics to a "strong-buy" rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $77.67.

Corcept Therapeutics Trading Down 4.4%

Shares of Corcept Therapeutics stock traded down $1.80 on Thursday, hitting $38.67. 840,233 shares of the company's stock traded hands, compared to its average volume of 2,174,640. The company has a fifty day moving average of $37.41 and a two-hundred day moving average of $61.15. Corcept Therapeutics has a one year low of $28.66 and a one year high of $117.33. The company has a market capitalization of $4.11 billion, a price-to-earnings ratio of 47.15 and a beta of 0.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.92 and a quick ratio of 2.85.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The business had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. During the same quarter in the previous year, the firm posted $0.26 earnings per share. The company's revenue for the quarter was up 11.1% compared to the same quarter last year. As a group, sell-side analysts expect that Corcept Therapeutics will post 1.36 earnings per share for the current year.

Insider Activity

In other news, insider William Guyer sold 20,000 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $40.87, for a total value of $817,400.00. Following the completion of the sale, the insider directly owned 1,235 shares of the company's stock, valued at $50,474.45. This represents a 94.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director G Leonard Baker, Jr. bought 100,000 shares of the company's stock in a transaction dated Tuesday, March 17th. The stock was bought at an average price of $33.14 per share, for a total transaction of $3,314,000.00. Following the acquisition, the director directly owned 1,146,631 shares of the company's stock, valued at approximately $37,999,351.34. This represents a 9.55% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders sold 60,000 shares of company stock worth $2,241,035. 20.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Corcept Therapeutics

Institutional investors have recently bought and sold shares of the stock. Torren Management LLC bought a new position in Corcept Therapeutics during the 4th quarter valued at $25,000. Advisory Services Network LLC purchased a new position in Corcept Therapeutics during the 3rd quarter worth $25,000. Clearstead Advisors LLC grew its stake in shares of Corcept Therapeutics by 163.6% in the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company's stock worth $26,000 after acquiring an additional 193 shares in the last quarter. Atlas Capital Advisors Inc. bought a new stake in shares of Corcept Therapeutics in the 4th quarter worth $31,000. Finally, Hantz Financial Services Inc. raised its holdings in shares of Corcept Therapeutics by 113.7% in the fourth quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 524 shares during the last quarter. Institutional investors own 93.61% of the company's stock.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) in combination with nab‑paclitaxel for platinum‑resistant ovarian cancer — major commercial catalyst and the primary reason for the recent sharp rally. FDA Approves Lifyorli (BusinessWire)
• Positive Sentiment: Recent analyst support/upgrades: Truist moved CORT to "strong‑buy" and Wolfe Research raised its view (from underperform to peer perform), while H.C. Wainwright kept a Buy rating (with a lowered $60 PT) — these help sustain upside expectations after approval. Truist Upgrade (Zacks) Wolfe Upgrade (Benzinga)
• Positive Sentiment: Insider/director buy in mid‑March (reported purchase of ~100k shares) has been cited by market commentary as a confidence signal that amplified bullish positioning ahead of the FDA decision. Insider Buy & Catalyst Analysis (QuiverQuant)
• Neutral Sentiment: Trading was temporarily halted for a LULD pause during the sharp move — a market‑structure volatility control rather than company‑specific news. Market Reaction Coverage (Reuters)
• Neutral Sentiment: Expect elevated intraday volatility and volume as the market re‑prices CORT on the approval and new info (reports showed 30–48% intraday swings); that increases short‑term trading risk. Volatility Coverage (Reuters)
• Negative Sentiment: Multiple law firms have filed/issued investor alerts about securities‑class‑action suits tied to prior disclosures, alleged regulatory warnings and patent issues — these lawsuits create material legal and expense risk that can weigh on the stock. Hagens Berman Alert (GlobeNewswire)
• Negative Sentiment: Recent insider selling (William Guyer sold ~11,767 shares on Mar 20) reduces insider stake and may be viewed unfavorably by some investors, adding to downward pressure after the post‑approval run‑up. Insider Sale SEC Filing

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.